A novel therapeutic strategy for mycoplasma infectious diseases

Mycoplasma Infectious Diseases (MID) are systemic illnesses that cause vasculitis and neuritis. MID not only includes pneumonia but also diseases such as asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, and hematologic illnesses. The broader concept of MID encompasses acute to chronic phases with diverse symptoms. Therefore, it is often confusing and difficult to identify Mycoplasma-infected patients among those with incurable diseases, such as autoimmune diseases, rheumatic diseases, nervous system disorders, and hematological disorders. Regrettably, conventional diagnosis has only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. A cutting-edge technology has made it possible to measure the amount of specific antibodies to species-specific mycoplasma glycolipid-antigens. This new technology provides a reliable marker to follow the state of MID by monitoring antibody titer fluctuations. A novel therapeutic strategy based on new serological diagnostics is introduced in this review.